NICE (UK) will support the use of Fractional exhaled Nitric Oxide (FeNO) measurement in diagnosis and management of asthma.

Solna (Sweden) – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that
NICE (National Institute for Health and Care Excellence) has notified
stakeholders that the final guidelines recommending the use of Aerocrine’s NIOX
MINO® and NIOX VERO® to improve diagnosis and management of a type of asthma
caused by airway inflammation are expected to be published in April.
NICE develops evidence-based guidelines that help the National Health Services,
local authorities and the wider medical community deliver high-quality
healthcare to the British public. The new guidelines recommend that FeNO tests
be used to assist with the diagnosis and management of asthma caused by allergic
airway inflammation in adults and children who, after initial clinical
examination, are considered to have an intermediate probability of having asthma
and when FeNO testing is intended to be done in combination with other
diagnostic options.

Aerocrine’s NIOX MINO® and NIOX VERO® measure FeNO levels. Healthcare
professionals use FeNO testing to identify allergic airway inflammation in
patients with suspected asthma, to help predict patient response to
corticosteroid therapy and to help assess patient adherence to the prescribed
therapy. NIOX MINO and NIOX VERO produce reliable and accurate results and are
built on the recommendations from the American Thoracic Society (ATS) and the
European Respiratory Society (ERS).

The Stakeholder Notification included the following information:

The guidelines will look at how NIOX MINO and NIOX VERO technologies can improve
diagnosis and management of asthma.

The implementation pack, which includes case studies carried out in hospitals
and GP surgeries, will provide useful information and practical advice on
putting this guidance into practice. Respiratory clinicians from several NHS
sites, who participated in the development of this pack, reported that benefits
of adopting these technologies can include:

  ·
Reduced numbers of non-elective admissions associated with asthma

  ·
Reduced risk of readmission for patients admitted because of asthma after
discharge from hospital

  ·
Improved and earlier diagnosis of asthma in adults and children

  ·
Reduced need for invasive lung function tests to diagnose or manage asthma

  ·
Ease of use for patients and suitably trained staff

Aerocrine will provide additional information once the final guidelines are
published according to the dates given by NICE.

For more information, contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788 379, +970
368 0336

David Plotts, Vice President, UK Managing Director and EU/RoW Sales.   +44 (0)
7891 433239

Dr. Kathy Rickard, Chief Medical Officer, Aerocrine AB +919 749 6708

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in technology to monitor and manage airway inflammation, Aerocrine
markets NIOX MINO® and NIOX VERO® (EU) Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm
Stock Exchange in 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 5:00 PM on 03/21/2014